TEANECK, NJ—Pharmaceutical manufacturer Kyorin U.S.A. Inc., a subsidiary of Tokyo, Japan-based Kyorin Pharmaceutical Co. Ltd., has renewed its 2,370-square-foot lease at Glenpointe Centre West, located at 500 Frank W. Burr Blvd. in Teaneck. The Glenpointe office campus is owned and operated by Alfred Sanzari Enterprises of Hackensack, NJ. Sanzari negotiated the transaction in-house.
Kyorin U.S.A. Inc. has been a tenant at Glenpointe since 2001, according to Tami Mizuno, the company's treasurer.
“Glenpointe is a well-maintained, quality office complex with a location convenient to New York/New Jersey airports and major highways,” says Mizuno. “The fact that Glenpointe has a full-service Marriott hotel on-site is a big plus because we often have clients and employees visiting from around the world. We couldn't be more pleased with this location.”
Founded in 1923, Kyorin Pharmaceutical Co. Ltd.'s core products focus on respiratory medicine, otolaryngology, urology and infectious diseases. Kyorin also manufactures and markets consumer health care products.
“This transaction is a clear demonstration that by virtue of its location, design and amenities, Glenpointe is an excellent choice for world-class organizations,” says Jerry L. Barta, Sanzari vice-president/director of leasing and marketing. “We are pleased to have Kyorin U.S.A. Inc. remain a tenant here for years to come.”
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.